Stem cell therapy is showing significant promise in treating silicosis, an irreversible fibrotic lung disease caused by silica exposure. Current treatments only slow progression, but stem cells offer a potential to halt and even reverse lung damage.
Silicosis develops from persistent lung scarring due to chronic silica inhalation. Stem cells can target key disease pathways, including inflammation and fibrosis, using their regenerative and immunomodulatory properties. Researchers are studying Mesenchymal Stem Cells (MSCs), Airway Basal Stem Cells (ABSCs), and Induced Pluripotent Stem Cells (iPSCs) for their therapeutic potential.
Challenges remain in standardizing production, improving cell delivery to the lungs, and ensuring patient safety. However, innovative strategies like CRISPR-engineered stem cells and nano-delivery systems are being developed to enhance treatment efficacy. These advancements offer a new path toward managing silicosis and improving patient outcomes.